VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617-341-6100
http://www.vrtx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,500

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey Marc LeidenChairman, CEO & Pres4.78M48.72M1956
Dr. David M. AltshulerChief Scientific Officer & Exec. VP of Global Research1.25M3.2M1965
Mr. Michael J. PariniExec. VP and Chief Legal & Admin. Officer1.5M1.22M1975
Mr. Amit K. SachdevExec. VP & Chief Regulatory Officer1.15M9M1968
Mr. Thomas GraneyExec.427.26kN/A1965
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for treating pain; CTX001, which is in Phase I/II trial for treating beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc., as well as a research collaboration with Arbor Biotechnologies to discover DNA endonucleases for cystic fibrosis and four other diseases. It also has a collaboration with X-Chem, Inc. to develop DNA-encoded DEX libraries. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate Governance

Vertex Pharmaceuticals Incorporated’s ISS Governance QualityScore as of February 1, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.